Loading...
The Treatment of Hormone-Refractory Prostate Cancer: Docetaxel and Beyond
Two randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of meta...
Saved in:
| Main Author: | |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MedReviews, LLC
2006
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1578715/ https://ncbi.nlm.nih.gov/pubmed/17021642 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|